Dr Johansson is head of the Immvirx quality assurance program. She is a molecular biologist with over 20 years experience in the biotechnology sector. Dr Johansson, who holds a PhD in molecular virology from the University of Kalmar, Sweden, headed up the quality assurance program in Viralytics including through its acquisition by Merck and Co. in 2018. She has extensive experience in the fundamentals of oncolytic viruses and its application in both pre-clinical and clinical settings. Dr Johansson has performed key roles in assay development and monitoring data from laboratory assays generated by oncolytic viruses in the clinical setting.